Search
Mevociclib
go.drugbank.com/drugs/DB21454InvestigationalMevociclib is under investigation in clinical trial NCT03134638 (A Study of SY-1365 in Adult Patients With Advanced Solid Tumors). Mevociclib has a monoisotopic molecular weight of 586.26 Da. … Mevociclib is a small molecule drug. The usage of the INN stem '-ciclib' in the name indicates that Mevociclib is a cyclin dependant kinase inhibitor.
Risvodetinib
go.drugbank.com/drugs/DB21602InvestigationalRisvodetinib has a monoisotopic molecular weight of 574.28 Da. … Risvodetinib is a small molecule drug. The usage of the INN stem '-tinib' in the name indicates that Risvodetinib is a tyrosine kinase inhibitor.
Cenacitinib
go.drugbank.com/drugs/DB21735InvestigationalCenacitinib has a monoisotopic molecular weight of 431.15 Da. … Cenacitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Cenacitinib is a Janus kinase inhibitor.
Gabexate
go.drugbank.com/drugs/DB12831InvestigationalGabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. … Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and pancreatitis.[A19218,A19219,A19220]
Danegaptide
go.drugbank.com/drugs/DB11821InvestigationalDanegaptide has been investigated for the treatment of Focus of Study is STEMI.
Bectumomab
go.drugbank.com/drugs/DB04962ExperimentalBectumomab (marketed under the trade name LymphoScan®) is a mouse monoclonal antibody and which it's used to treat non-Hodgkin's lymphoma. It has a radioisotope, technetium (99m TC) which it's added.
SUVN-502
go.drugbank.com/drugs/DB06140InvestigationalSUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer … ’s and Schizophrenia, an unmet medical need.
Tilbroquinol
go.drugbank.com/drugs/DB13222ApprovedIn Morocco, the drug has been limited to use in the treatment of intestinal amoebiasis. … Tilbroquinol was approved in France, Morocco, and Saudi Arabia but it has been withdrawn in France and Saudi Arabia markets mainly due to its hepatotoxicity risk outweighing the drug benefit [L5467].